sing artificial intelligence to optimize antibiotic dosing in the treatment of sepsis
Recruiting
- Conditions
- A41.9Sepsis, unspecified
- Registration Number
- DRKS00032970
- Lead Sponsor
- niverstitätsklinikum Knappschaftskrankenhaus Bochum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Intensive care treatment
- Inclusion within 72 h after diagnosis of sepsis (according to sepsis-3-definition)
- Inclusion within 24 h after initiation of treatment with piperacillin/tazobactam or meropenem
- Antibiotic treatment with meropenem or piperacillin/tazobactam.
Exclusion Criteria
- Refusal of study participation by patient/authorized representative
- Pregnancyandbreastfeeding
- Manifest anemia with hemoglobin value <8g/dl
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Predict antibiotic serum concentration (ASC) of piperacillin/tazobactam or meropenem on day 1 therapy.
- Secondary Outcome Measures
Name Time Method - Prediction of ASK of piperacillin/tazobactam or meropenem during the course of therapy on days 2,3,4,5,6,7 and 8.<br>- Influence of ASC on 30-day mortality.<br>- Influence of ASC on the course of the SOFA score (Delta-SOFA)<br>- Occurrence of antibiotic resistance under therapy<br>- Influence of ASC on the incidence of acute renal renal failure<br>- Influence of ASC on the incidence of acute liver injury